On April 8, 2021 ImmVira reported that the company will be presenting its first innovative product, MVR-T3011, at the 2021 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting on June 4-8 2021 (Press release, Immvira, APR 8, 2021, View Source [SID1234577761]). Results from the first Phase 1 study of MVR-T3011 as an intratumoral injection in patients with advanced solid tumors in the United States and Australia will be presented.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, the company will be presenting its latest preclinical research progress on the company’s MVR-T3011 administered as an intravenous infusion at the 112th Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) on April 10-15 and May 17-21, 2021.